✨ Your Portfolio is fetched and updated from zerodha.
Market Cap
₹43,660 Cr.
P/E
27.62
About
Biocon Limited is an innovation-led global biopharmaceuticals company that manufactures biotechnology products and research services. It focuses on enhancing affordable access to therapies for chronic… Read more
Biocon Limited is an innovation-led global biopharmaceuticals company that manufactures biotec… Read more
Low
218
52W Range
High
396
Quick View
  • 1d
  • 1m
  • 6m
  • YTD
  • 1y
  • 3y
  • 5y
  • 10y
  • max

Company Timeline

Custom financial statement
Edit rows
Forensics

9 Yes

Positive for this company

1 Neutral

Neutral for this company

7 No

Negative for this company

0 No Data

Insufficient data to analyse

Market Share
1.52 %
(as of Jul 22)
Anti - Diabetes - Market Share
0.27 %
(as of Jul 22)
Anti-Infectives - Market Share
4.21 %
(as of Nov 21)
Antineo Plastic - Market Share
1.04 %
(as of Nov 21)
Blood Related - Market Share
27 %
(as of Mar 19)
CANMAb - Market Share
0.05 %
(as of Jul 22)
Cardiovascular - Market Share
Revenue mix

Product Wise Break-Up

Location Wise Break-Up

Operating Profit Break-Up

Asset Break-Up

Operational Metrics

    Select a Metric
    • Domestic Sales Growth - YoY (%)
    • R&D as a % of Total Sales (%)
    Peer Comparison
    Brands
    CANMAb
    Insugen
    Suppliers
    • Sobha Ltd.
    • Alkyl Amines Chemicals Ltd.
    • B.L. Kashyap and Sons Ltd.
    FAQs on Biocon Ltd. Business

    Biocon Limited is a global biopharmaceuticals company focusing on developing and manufacturing innovative biologics, biosimilars, and APIs for chronic conditions. They also have a pipeline of novel assets in immunotherapy.

    Biocon major competitors are Concord Biotech, Advanced Enzyme, Fermenta Biotech, Glaxosmithkline Phar, Ajanta Pharma, Glenmark Pharma, Ipca Laboratories.
    Market Cap of Biocon is ₹45,479 Crs.
    While the median market cap of its peers are ₹37,452 Crs.

    Biocon seems to be less financially stable compared to its competitors.
    Altman Z score of Biocon is 1.53 and is ranked 8 out of its 8 competitors.

    Company Filing
    2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010
    Annual Report FY24 FY23 FY22 FY21 FY20 FY19 FY18 FY17 FY16 FY15 FY14 FY13 FY12 FY11 FY10
    Earnings Release Mar Jun Sep Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec
    Investor Presentation Mar Jun Sep Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec
    Conference Call Mar Jun Sep Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec
    Conference Call SummaryCon Call Summary Sep Mar Jun Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec
    Discussions & Analysis